BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23285063)

  • 21. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
    Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
    Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of immunity induced by M2e of influenza virus.
    Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
    Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.
    Wang Y; Deng L; Gonzalez GX; Luthra L; Dong C; Ma Y; Zou J; Kang SM; Wang BZ
    Adv Healthc Mater; 2020 Jan; 9(2):e1901176. PubMed ID: 31840437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Construction, expression and immunogenicity analysis of a fusion protein containing M2e of influenza A virus fused to a modified Pseudomonas aeruginosa exotoxin A].
    Xu Y; Yao LH; Chen AJ; Guo JQ; Liu XY; Bo H; Liu LQ; Shu YL; Zhang ZQ
    Bing Du Xue Bao; 2010 May; 26(3):189-94. PubMed ID: 20572339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
    Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
    Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A biomimetic VLP influenza vaccine with interior NP/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy.
    Wei J; Li Z; Yang Y; Ma X; An W; Ma G; Su Z; Zhang S
    Vaccine; 2020 Aug; 38(38):5987-5996. PubMed ID: 32713681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Characterization the immunogenicity of recombinant VP2 of infectious bursal disease virus containing N-terminal M2e of avian influenza virus].
    Tang Y; Gong Y; Wang Y; Lu J; Wu P; Gao F; Chen T; He J; Hou J
    Wei Sheng Wu Xue Bao; 2012 Jun; 52(6):753-9. PubMed ID: 22934356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
    Kaminaka K; Matsuda J; Nozaki C
    Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
    Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
    PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
    Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development.
    Li M; Guo P; Chen C; Feng H; Zhang W; Gu C; Wen G; Rao VB; Tao P
    Front Immunol; 2021; 12():745625. PubMed ID: 34712234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
    Khodamoradi S; Shenagari M; Kheiri MT; Sabahi F; Jamali A; Heidari A; Ashrafkhani B
    Arch Virol; 2018 Apr; 163(4):877-886. PubMed ID: 29270718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
    Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
    Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
    Liu W; Zou P; Chen YH
    Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.